Login to Your Account



Clinic Roundup


Friday, September 28, 2012
• BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed a Phase I study of BMN-111, an analogue of C-type natriuretic peptide, for achondroplasia, the most common form of human dwarfism.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription